Weight-Loss Drugs, Hormones, and Midlife: What Women Need to Know

For many women, midlife brings unexpected changes. Weight that once came off easily may become harder to lose. Sleep can become more disrupted. Energy levels shift. And metabolism often seems to work differently than it did a decade earlier.

These are exactly the kinds of questions Lauren M. Sparks, PhD, a senior investigator at the AdventHealth Translational Research Institute, is working to answer. Her research focuses on how metabolism, hormones, and aging intersect to shape women’s health.

“We are beginning to understand that hormones, metabolism, and aging are deeply connected, and that understanding those connections may help us deliver more personalized care for women,” says Dr. Sparks.

At the same time, a new class of medications known as GLP-1 receptor agonists, including semaglutide and tirzepatide, has transformed the treatment of obesity and metabolic disease. Many people know these medications by brand names such as Ozempic, Wegovy, and Mounjaro. Millions now use them to help regulate blood sugar, reduce appetite, and support weight loss.

As more women in their 40s, 50s, and 60s begin using these medications, researchers are asking an important question. How might GLP-1 medications interact with the hormonal changes of menopause?

Many women in midlife are also considering menopause hormone therapy (MHT) to help manage symptoms such as hot flashes, sleep disruption, and metabolic changes. As the use of both treatments grows, scientists are beginning to explore how they may influence each other.

During menopause, declining estrogen levels can affect metabolism, body composition, and insulin sensitivity. Many women notice shifts in weight distribution and there is an increased risk of cardiometabolic disease during this transition.

GLP-1 medications influence some of these same metabolic systems. These drugs mimic a naturally occurring hormone that signals fullness to the brain, slows stomach emptying, and helps regulate blood sugar.

Because both estrogen and GLP-1 pathways influence metabolism, researchers have begun studying whether hormonal status may affect how women respond to these medications.

Early research suggests it may be possible. In one observational study of postmenopausal women taking the GLP-1 medication tirzepatide, those using menopause hormone therapy appeared to lose more weight than women taking the medication alone. Researchers caution that these findings are preliminary and do not prove hormone therapy directly enhances weight loss. However, they highlight an important new area of investigation in women’s health.

As GLP-1 medications become more widely used, understanding how they interact with hormonal changes during midlife will become increasingly important. Scientists are now exploring how menopause influences metabolism, whether GLP-1 medications work differently before and after menopause, and how hormone therapy might affect treatment outcomes.

If you are taking, or considering, a GLP-1 medication and are also thinking about menopause hormone therapy, it may be helpful to discuss a few key questions with your physician.

• Could a GLP-1 medication be appropriate for my health goals and medical history?
• How might menopause or hormonal changes affect my metabolism and weight?
• If I am considering hormone replacement therapy, could it influence how I respond to a GLP-1 medication?
• Are there any medications or supplements I take that could interact with GLP-1 medications or hormone therapy?
• What lifestyle changes should accompany these treatments to support long-term health?
• How will we monitor my metabolic health, heart health, and overall progress over time?

The intersection of metabolism, hormones, and aging is quickly becoming one of the most important areas of women’s health research. Understanding these connections may help physicians deliver more personalized care for women throughout every stage of life.